Microparticulate/Nanoparticulate Powders of a Novel Nrf2 Activator and an Aerosol Performance Enhancer for Pulmonary Delivery Targeting the Lung Nrf2/Keap-1 Pathway.

Muralidharan, Priya; Hayes, Don; Black, Stephen M; Mansour, Heidi M

Muralidharan, Priya; Hayes, Don; Black, Stephen M; Mansour, Heidi M.

Afiliación

Muralidharan P; College of Pharmacy, Skaggs Pharmaceutical Sciences Center, The University of Arizona, Tucson, AZ, 85721, USA.
Hayes D; Departments of Pediatrics and Internal Medicine, Lung and Heart-Lung Transplant Programs, The Ohio State University College of Medicine, Columbus, OH 43205, USA; The Davis Heart and Lung Research Institute, The Ohio State University College of Medicine, Columbus, OH 43205, USA.
Black SM; Department of Medicine, Division of Translational and Regenerative Medicine, The University of Arizona, Tucson, AZ, 85724, USA.
Mansour HM; College of Pharmacy, Skaggs Pharmaceutical Sciences Center, The University of Arizona, Tucson, AZ, 85721, USA; Institute of the Environment, The University of Arizona, Tucson, AZ 85721, USA; National Cancer Institute Comprehensive Cancer Center, The University of Arizona, Tucson, AZ 85721, USA; The

Mol Syst Des Eng ; 1(1): 48-65, 2016.

Article en En | MEDLINE | ID: mdl-27774309

Palabras clave

acute lung injury (ALI); chronic obstructive pulmonary disease (COPD); dry powder inhaler (DPI); human inhaler device; in vitro aerosol predictive lung deposition modeling; nanotechnology; pulmonary endothelial disease; pulmonary hypertension (PH); solid state particle engineering design; targeted pulmonary drug delivery

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Mol Syst Des Eng Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google